Trevi Therapeutics Inc (TRVI)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Jennifer L. Good |
| Employees: | 20 |
| Web site: | trevitherapeutics.com |
|
195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, 06510
203-304-2499
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Trevi Therapeutics is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Please log in first to see chart